Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
University of Vermont
30 participants
Nov 5, 2024
OBSERVATIONAL
Conditions
Summary
Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Eligibility
Inclusion Criteria5
- Age ≥18 years
- Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
- Eastern Cooperative Oncology Group (ECOG) performance status ≤3
- Expected survival of at least 6 months
- Ability to provide consent
Exclusion Criteria2
- Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
- Hematopoietic stem cell transplantation expected within 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood will be collected from one cohort to identify potential blood biomarkers.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06692894